No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post hoc analysis from the randomized controlled PRE-D trial
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes : A post hoc analysis from the randomized controlled PRE-D trial. / Clemmensen, Kim K. B.; Blond, Martin B.; Amadid, Hanan; Bruhn, Lea; Vistisen, Dorte; Karstoft, Kristian; Persson, Frederik; Ried-Larsen, Mathias; Holst, Jens J.; Wewer Albrechtsen, Nicolai J.; Torekov, Signe S.; Quist, Jonas S.; Jorgensen, Marit E.; Faerch, Kristine.
In: Diabetes, Obesity and Metabolism, Vol. 23, No. 2, 2021, p. 530-539.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes
T2 - A post hoc analysis from the randomized controlled PRE-D trial
AU - Clemmensen, Kim K. B.
AU - Blond, Martin B.
AU - Amadid, Hanan
AU - Bruhn, Lea
AU - Vistisen, Dorte
AU - Karstoft, Kristian
AU - Persson, Frederik
AU - Ried-Larsen, Mathias
AU - Holst, Jens J.
AU - Wewer Albrechtsen, Nicolai J.
AU - Torekov, Signe S.
AU - Quist, Jonas S.
AU - Jorgensen, Marit E.
AU - Faerch, Kristine
PY - 2021
Y1 - 2021
N2 - Aim: To assess the effects of dapagliflozin, metformin and exercise treatment on changes in plasma glucagon concentrations in individuals with overweight and HbA1c-defined prediabetes.Materials and Methods: One-hundred and twenty individuals with overweight (body mass index >= 25 kg/m(2)) and prediabetes (HbA1c of 39-47 mmol/mol) were randomized to a 13-week intervention with dapagliflozin (10 mg once daily), metformin (850 mg twice daily), exercise (30 minutes of interval training 5 days per week) or control (habitual living). A 75-g oral glucose tolerance test (OGTT) (0, 30, 60 and 120 minutes) was administered at baseline, at 13 weeks (end of intervention) and at 26 weeks (end of follow-up). Linear mixed effects models with participant-specific random intercepts were used to investigate associations of the interventions with fasting plasma glucagon concentration, insulin/glucagon ratio and glucagon suppression during the OGTT.Results: At baseline, the median (Q1; Q3) age was 62 (54; 68) years, median fasting plasma glucagon concentration was 11 (7; 15) pmol/L, mean (SD) HbA1c was 40.9 (2.3) mmol/mol and 56% were women. Compared with the control group, fasting glucagon did not change in any of the groups from baseline to the end of the intervention (dapagliflozin group: -5% [95% CI: -29; 26]; exercise group: -8% [95% CI: -31; 24]; metformin group: -2% [95% CI: -27; 30]). Likewise, there were no differences in insulin/glucagon ratio and glucagon suppression during the OGTT between the groups.Conclusions: In individuals with prediabetes, 13 weeks of treatment with dapagliflozin, metformin or exercise was not associated with changes in fasting or post-OGTT glucagon concentrations.
AB - Aim: To assess the effects of dapagliflozin, metformin and exercise treatment on changes in plasma glucagon concentrations in individuals with overweight and HbA1c-defined prediabetes.Materials and Methods: One-hundred and twenty individuals with overweight (body mass index >= 25 kg/m(2)) and prediabetes (HbA1c of 39-47 mmol/mol) were randomized to a 13-week intervention with dapagliflozin (10 mg once daily), metformin (850 mg twice daily), exercise (30 minutes of interval training 5 days per week) or control (habitual living). A 75-g oral glucose tolerance test (OGTT) (0, 30, 60 and 120 minutes) was administered at baseline, at 13 weeks (end of intervention) and at 26 weeks (end of follow-up). Linear mixed effects models with participant-specific random intercepts were used to investigate associations of the interventions with fasting plasma glucagon concentration, insulin/glucagon ratio and glucagon suppression during the OGTT.Results: At baseline, the median (Q1; Q3) age was 62 (54; 68) years, median fasting plasma glucagon concentration was 11 (7; 15) pmol/L, mean (SD) HbA1c was 40.9 (2.3) mmol/mol and 56% were women. Compared with the control group, fasting glucagon did not change in any of the groups from baseline to the end of the intervention (dapagliflozin group: -5% [95% CI: -29; 26]; exercise group: -8% [95% CI: -31; 24]; metformin group: -2% [95% CI: -27; 30]). Likewise, there were no differences in insulin/glucagon ratio and glucagon suppression during the OGTT between the groups.Conclusions: In individuals with prediabetes, 13 weeks of treatment with dapagliflozin, metformin or exercise was not associated with changes in fasting or post-OGTT glucagon concentrations.
KW - exercise
KW - glucagon
KW - metformin
KW - obesity
KW - prediabetes
KW - sodium-glucose co-transporter-2 inhibitor
KW - COTRANSPORTER 2 INHIBITION
KW - BETA-CELL FUNCTION
KW - WEIGHT-LOSS
KW - INSULIN-RESISTANCE
KW - GLUCOSE
KW - RESPONSES
KW - GLP-1
U2 - 10.1111/dom.14246
DO - 10.1111/dom.14246
M3 - Journal article
C2 - 33146457
VL - 23
SP - 530
EP - 539
JO - Diabetes, Obesity and Metabolism
JF - Diabetes, Obesity and Metabolism
SN - 1462-8902
IS - 2
ER -
ID: 252469514